CDT Equity (CDT) EBITDA (2022 - 2026)
CDT Equity's (CDT) quarterly EBITDA came in at -$3.0 million in Q2 2026, up 39.38% on a YoY basis from -$2.2 million in Q2 2025, and up 18.86% quarter-over-quarter from -$3.7 million in Q1 2026.
Analysis
CDT Equity (CDT) EBITDA (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has reported EBITDA for 5 consecutive years, with -$3.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA rose 39.38% year-over-year to -$3.0 million; the trailing twelve-month figure through Jun 2026 stood at -$34.9 million (down 95.25% YoY), and the FY2025 full-year result was -$36.8 million, down 138.67% from the prior year.
- EBITDA grew to -$3.0 million in Q2 2026 per CDT's latest filing, from -$3.7 million in the prior quarter.
- Across five years, EBITDA topped out at -$263718.0 in Q1 2022 and bottomed at -$21.2 million in Q4 2025.
- Historically, EBITDA has averaged -$3.7 million across 5 years, with a median of -$3.0 million in 2024.
- The sharpest annual moves came in 2023 and 2024: EBITDA jumped 53.91% in 2023, then plunged 1251.4% in 2024.
- Over 5 years, EBITDA stood at -$1.7 million in 2022, then tumbled by 47.37% to -$2.5 million in 2023, then slumped by 42.4% to -$3.5 million in 2024, then slumped by 503.44% to -$21.2 million in 2025, then surged by 85.84% to -$3.0 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$3.0 million, -$3.7 million, and -$21.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 640.79 Bn | 620.03 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 445.95 Bn | 439.38 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 357.40 Bn | 350.26 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 267.40 Bn | 259.71 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Pfizer | 156.52 Bn | 144.82 Bn | 10.94 Bn | 4.27 Bn |
| 6 | Sanofi | 52.15 Bn | 44.77 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 43.02 Bn | 43.02 Bn | - | -505.13 Mn |
| 8 | Incyte | 24.59 Bn | 20.06 Bn | 1.57 Bn | 697.90 Mn |
| 9 | United Therapeutics | 21.31 Bn | 18.64 Bn | 683.80 Mn | 330.80 Mn |
| 10 | CDT Equity | 179,140.97 | 179,140.97 | - | -3.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.00 Mn |
| Mar 31, 2026 | -3.70 Mn |
| Dec 31, 2025 | -21.20 Mn |
| Sep 30, 2025 | -7.03 Mn |
| Jun 30, 2025 | -4.95 Mn |
| Mar 31, 2025 | -3.62 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Sep 30, 2024 | -5.81 Mn |
| Jun 30, 2024 | -3.14 Mn |
| Mar 31, 2024 | -2.96 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -430,000.00 |
| Jun 30, 2023 | -888,000.00 |
| Mar 31, 2023 | -1.52 Mn |
| Dec 31, 2022 | -1.67 Mn |
| Sep 30, 2022 | -933,000.00 |
| Jun 30, 2022 | -279,420.00 |
| Mar 31, 2022 | -263,718.00 |